Hypertrophic Cardiomyopathy (HCM)

Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, causing unexplained thickening of the heart muscle; most cases go undetected because symptoms are mild or mistaken for deconditioning.
About Hypertrophic Cardiomyopathy
In numbers
  • HCM affects around 1 in 500 people in the general population, with a genotype frequency of about 1 in 200.
  • An estimated 700,000 people in the USA live with HCM, based on a prevalence of roughly 1 in 500 applied to the US population.
  • Most cases remain undiagnosed: guideline and registry estimates suggest the majority of affected individuals have never had a confirming echocardiogram.
  Special details
  • HCM is autosomal dominant, with 60 to 70 percent of genotype-positive cases linked to MYBPC3 or MYH7 variants.
  • Around 70 percent of symptomatic patients have the obstructive form, oHCM, defined by a left ventricular outflow tract gradient of 30 mmHg or more.
  • Median age at diagnosis falls between 30 and 50 years, though HCM is also the leading cause of sudden cardiac death in young people and competitive athletes.
Signs and symptoms of Hypertrophic Cardiomyopathy
Echocardiography confirms HCM simply and reliably, yet diagnosis is often late or incidental. Many patients attribute exertional symptoms to deconditioning, and first-degree relatives are rarely cascade-screened; some present first with a sudden arrhythmic event.
Exertional breathlessness

Exertional breathlessness

Dyspnoea on exertion, often the earliest and most common symptom.

Chest pain

Chest pain

Atypical chest pain not explained by coronary disease.

Palpitations and pre-syncope

Palpitations and pre-syncope

Awareness of irregular heartbeat, light-headedness or fainting on exertion.

Murmur

Murmur

A systolic ejection murmur that grows louder with the Valsalva manoeuvre.

Arrhythmia and heart failure

Arrhythmia and heart failure

Atrial fibrillation, ventricular arrhythmia and progressive heart failure as disease advances.

Key challenges from product development to launch

Strategy and Business

Strategy and Business

  • The wrong disease or indication selected for investment
  • Indications tackled in the wrong order due to shaky success estimates
  • R&D returns slipping below the cost of capital
Clinical Development

Clinical Development

  • Trials delayed by low patient recruitment
  • High screen-failure rates that raise trial cost
  • Mixed cohorts that make the signals difficult to detect
HEOR, Access & Value

HEOR, Access & Value

  • A value case that arrives too late or is underdeveloped
  • Eligible population under-counted, budget-impact case unsubstantiated
  • Approved by the regulator, delayed at HTA
Medical Affairs

Medical Affairs

  • Fragmented, differently-coded healthcare data
  • Diagnostic delay that is long and unequal
  • No shared evidence base across functions
Launch and Commercial

Launch and Commercial

  • Launch planned without a view of the number of findable patients
  • Targeting too broad a population slows early uptake
  • RWE started too late to build the case

How Volv Global Helps

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.

Case Studies about Cardiology diseases

No posts found.

Insights